{"id":"meningococcal-b","safety":{"commonSideEffects":[{"rate":"50-70","effect":"Injection site pain/erythema"},{"rate":"10-20","effect":"Fever"},{"rate":"20-40","effect":"Myalgia"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108795","moleculeType":"Vaccine component"},"_dailymed":{"setId":"fd5652b6-5ae4-437e-a456-47deaf500794","title":"PENBRAYA (MENINGOCOCCAL GROUPS A, B, C, W, AND Y VACCINE) KIT [PFIZER LABORATORIES DIV PFIZER INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant proteins from the meningococcal serogroup B capsule and outer membrane, which trigger both humoral and cellular immune responses. This generates protective antibodies and immune memory that prevent infection by serogroup B meningococci, the leading cause of bacterial meningitis and septicemia in developed countries.","oneSentence":"Meningococcal B vaccine stimulates the immune system to produce antibodies against serogroup B Neisseria meningitidis, preventing meningococcal disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:51.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroup B in infants, children, adolescents, and adults"}]},"trialDetails":[{"nctId":"NCT04350138","phase":"PHASE2","title":"Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-29","conditions":"Gonococcal Infection","enrollment":2606},{"nctId":"NCT05766904","phase":"PHASE3","title":"Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-04","conditions":"Gonorrhea, Sexually Transmitted Infection","enrollment":150},{"nctId":"NCT05935176","phase":"PHASE4","title":"Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-20","conditions":"Epidemic Meningitis","enrollment":660},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT07395739","phase":"PHASE1","title":"A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)","startDate":"2026-02-24","conditions":"Neisseria Meningitidis Serogroup B","enrollment":30},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06832514","phase":"PHASE4","title":"Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons","status":"RECRUITING","sponsor":"University Ghent","startDate":"2025-01-31","conditions":"Meningococcal Meningitis, Serogroup B, Transgender Persons, Sex Differences in Immune Response","enrollment":250},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT06128733","phase":"PHASE1, PHASE2","title":"Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-10-31","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1215},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT07197762","phase":"PHASE4","title":"MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-11-04","conditions":"Neisseria Meningitidis","enrollment":125},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT07252804","phase":"PHASE4","title":"Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-01","conditions":"Autoimmune Rheumatologic Disease","enrollment":263},{"nctId":"NCT06995430","phase":"PHASE3","title":"A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-07-07","conditions":"Meningitis","enrollment":226},{"nctId":"NCT04166656","phase":"PHASE3","title":"Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-09-15","conditions":"Splenectomy","enrollment":84},{"nctId":"NCT04825223","phase":"PHASE1","title":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-29","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":576},{"nctId":"NCT04084769","phase":"PHASE3","title":"Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-03","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":570},{"nctId":"NCT06113198","phase":"PHASE4","title":"A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-11-10","conditions":"Meningitis, Meningococcal","enrollment":50},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06446752","phase":"PHASE3","title":"BIYELA - Bexsero Immunisation in Young Women in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-08-14","conditions":"Gonorrhea, Gonorrhea of Pharynx, Gonorrhea of Anus","enrollment":1100},{"nctId":"NCT04886154","phase":"PHASE1, PHASE2","title":"A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-14","conditions":"Infections, Meningococcal","enrollment":1440},{"nctId":"NCT05082285","phase":"PHASE2","title":"A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-11-29","conditions":"Infections, Meningococcal","enrollment":724},{"nctId":"NCT06033261","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-09-06","conditions":"Genital Herpes","enrollment":365},{"nctId":"NCT05873751","phase":"","title":"A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-04-24","conditions":"Gonorrhea, Chlamydia, Meningococcal Vaccines","enrollment":1307378},{"nctId":"NCT04415424","phase":"PHASE3","title":"Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2021-07-08","conditions":"Neisseria Gonorrheae Infection","enrollment":650},{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723},{"nctId":"NCT04318548","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-25","conditions":"Infections, Meningococcal","enrollment":945},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT04440176","phase":"PHASE2","title":"A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":309},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT06025487","phase":"PHASE2","title":"Meningococcal B Vaccine in Patients with Asplenia","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-03-12","conditions":"Splenectomy; Status","enrollment":80},{"nctId":"NCT04722003","phase":"PHASE2","title":"Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":"Gonorrhoea","enrollment":52},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT04893811","phase":"PHASE4","title":"Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-18","conditions":"Meningococcal Vaccine","enrollment":53},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT04597424","phase":"PHASE3","title":"Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-01-19","conditions":"Unsafe Sex, Risk-Taking","enrollment":556},{"nctId":"NCT04707391","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-25","conditions":"Meningitis, Meningococcal","enrollment":1250},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT06314880","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-07-22","conditions":"Healthy Volunteers","enrollment":300},{"nctId":"NCT04645966","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-26","conditions":"Meningococcal Vaccine","enrollment":326},{"nctId":"NCT04502693","phase":"PHASE3","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Meningococcal","enrollment":3657},{"nctId":"NCT04295733","phase":"","title":"Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency","status":"COMPLETED","sponsor":"Ospedale Policlinico San Martino","startDate":"2020-02-06","conditions":"Acquired Immunodeficiency","enrollment":98},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT06209398","phase":"PHASE4","title":"Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2018-05-24","conditions":"Hand, Foot and Mouth Disease","enrollment":510},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT01640652","phase":"PHASE1","title":"MenPF-1 - A New Vaccine Against Meningococcal Disease","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-08","conditions":"Serogroup B Meningococcal Disease","enrollment":52},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT03493919","phase":"PHASE4","title":"A Sourcing Study to Collect Human Blood Samples From Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-08","conditions":"Meningitis, Meningococcal","enrollment":1021},{"nctId":"NCT04440163","phase":"PHASE3","title":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":2431},{"nctId":"NCT04398849","phase":"","title":"Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)","status":"UNKNOWN","sponsor":"University of Adelaide","startDate":"2021-03-04","conditions":"Gonorrhea, Meningococcal Disease","enrollment":7100},{"nctId":"NCT05720767","phase":"PHASE1","title":"HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2022-11-04","conditions":"Relapsed or Refractory Lymphoma","enrollment":28},{"nctId":"NCT03636906","phase":"PHASE1, PHASE2","title":"Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-08","conditions":"Respiratory Syncytial Virus Infections","enrollment":201},{"nctId":"NCT04297436","phase":"NA","title":"Gonococcal Vaccine Study in Key Populations in Kenya","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-05-31","conditions":"Gonorrhea","enrollment":50},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT05212935","phase":"","title":"A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2022-05","conditions":"Vaccination, Rotavirus Infections, Meningococcal Infections","enrollment":2000},{"nctId":"NCT04239430","phase":"","title":"Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2020-11-26","conditions":"HIV/AIDS, Meningococcal Disease","enrollment":55},{"nctId":"NCT01894919","phase":"PHASE3","title":"Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-06","conditions":"Meningoccocal Disease, Meningococcal Meningitis","enrollment":851},{"nctId":"NCT02398396","phase":"NA","title":"Investigating Meningococcal Vaccines in Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-04","conditions":"Meningococcal Vaccines, Meningococcal Infections, Neisseria Meningitidis","enrollment":15},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT04358731","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-12-27","conditions":"Vaccine for Meningococcal Disease","enrollment":1640},{"nctId":"NCT03274102","phase":"PHASE4","title":"Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2017-04-22","conditions":"Hand, Foot and Mouth Disease","enrollment":780},{"nctId":"NCT04094883","phase":"PHASE4","title":"Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-10-09","conditions":"Neisseria Gonorrhoeae Infection","enrollment":11},{"nctId":"NCT04875819","phase":"PHASE4","title":"Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV","status":"RECRUITING","sponsor":"Thomas Benfield","startDate":"2021-04-28","conditions":"Hiv, Meningococcal Infections, Pneumococcal Infections","enrollment":55},{"nctId":"NCT00955682","phase":"PHASE3","title":"Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-25","conditions":"Infections, Meningococcal","enrollment":342},{"nctId":"NCT02569632","phase":"PHASE4","title":"Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2015-01","conditions":"Meningococcal Infections","enrollment":18},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT03125616","phase":"PHASE4","title":"Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2017-08-01","conditions":"Prematurity, Vaccination, Meningococcal Disease","enrollment":136},{"nctId":"NCT03509051","phase":"NA","title":"Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-01","conditions":"Hematopoietic Stem Cell Transplant, Meningococcal Vaccine","enrollment":40},{"nctId":"NCT01896596","phase":"PHASE4","title":"Hepatitis B Vaccination in Infants","status":"COMPLETED","sponsor":"Public Health England","startDate":"2013-07","conditions":"Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease","enrollment":300},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT02640677","phase":"","title":"Safety of 4CMenB Exposure During Pregnancy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-31","conditions":"Infections, Meningococcal","enrollment":2},{"nctId":"NCT02173704","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-11","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":225},{"nctId":"NCT01272180","phase":"PHASE2","title":"Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-08","conditions":"Invasive Meningococcal Disease","enrollment":484},{"nctId":"NCT00454987","phase":"PHASE4","title":"Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-16","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis, Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine","enrollment":288},{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT00228917","phase":"PHASE3","title":"Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-16","conditions":"Whole Cell Pertussis, Tetanus, Hepatitis B","enrollment":798},{"nctId":"NCT03587207","phase":"PHASE2","title":"Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-09","conditions":"Meningitis, Meningococcal","enrollment":520},{"nctId":"NCT02975596","phase":"NA","title":"MenB Vaccine: Implementation Via Information, Empowerment and Accessibility","status":"COMPLETED","sponsor":"University of Florida","startDate":"2016-12","conditions":"Meningococcal Vaccine","enrollment":1326},{"nctId":"NCT00463437","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-25","conditions":"Hepatitis B, Acellular Pertussis, Tetanus","enrollment":1437},{"nctId":"NCT01430689","phase":"PHASE4","title":"Maternal Flu Vaccine Trial in Bamako, Mali","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-09-12","conditions":"Influenza","enrollment":4193},{"nctId":"NCT02946385","phase":"PHASE2","title":"Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-11-15","conditions":"Infections, Meningococcal","enrollment":604},{"nctId":"NCT02712177","phase":"","title":"Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2008-08","conditions":"Meningococcal Infections","enrollment":4535},{"nctId":"NCT03089086","phase":"PHASE4","title":"South Australian Meningococcal B Vaccine Herd Immunity Study","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2017-04-01","conditions":"Meningococcal Disease","enrollment":34489},{"nctId":"NCT02212457","phase":"PHASE2","title":"Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-21","conditions":"Infections, Meningococcal","enrollment":1063},{"nctId":"NCT00718666","phase":"PHASE2","title":"The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-20","conditions":"Infections, Meningococcal","enrollment":387},{"nctId":"NCT00471081","phase":"PHASE2","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-05","conditions":"Infections, Meningococcal","enrollment":385},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT03682939","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2019-02-21","conditions":"Hiv, Meningitis, Meningococcal, HIV Infections","enrollment":55},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT00661713","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-06","conditions":"Meningococcal Disease","enrollment":1631},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT02583412","phase":"PHASE4","title":"Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-09","conditions":"Meningococcal Serogroup B","enrollment":120},{"nctId":"NCT00508261","phase":"PHASE3","title":"Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-01","conditions":"Infections, Meningococcal","enrollment":793}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":367,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bexsero"],"phase":"marketed","status":"active","brandName":"Meningococcal B","genericName":"Meningococcal B","companyName":"Canadian Immunization Research Network","companyId":"canadian-immunization-research-network","modality":"Biologic","firstApprovalDate":"","aiSummary":"Meningococcal B vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B, preventing meningococcal disease. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroup B in infants, children, adolescents, and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}